ACSS2 and neoplasm: VY-3–135 is a potent and selective ACSS2 inhibitor that inhibits ACSS2 activity both in vitro and in vivo and inhibits in vivo tumor growth in breast cancers with high ACSS2 expression [85, 103, 104].